UBS Group’s Tempest Therapeutics TPST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.43K | Sell |
4,533
-13,009
| -74% | -$31.4K | ﹤0.01% | 8581 |
|
|
2025
Q4 | $50.3K | Buy |
17,542
+6,153
| +54% | +$43.5K | ﹤0.01% | 7211 |
|
|
2025
Q3 | $117K | Buy |
11,389
+166
| +1% | +$1.44K | ﹤0.01% | 7010 |
|
|
2025
Q2 | $76.3K | Sell |
11,223
-13,677
| -55% | -$97.2K | ﹤0.01% | 7451 |
|
|
2025
Q1 | $239K | Buy |
24,900
+9,848
| +65% | +$112K | ﹤0.01% | 6424 |
|
|
2024
Q4 | $163K | Buy |
15,052
+14,406
| +2,230% | +$186K | ﹤0.01% | 6583 |
|
|
2024
Q3 | $11.8K | Buy |
+646
| New | +$13.2K | ﹤0.01% | 7664 |
|
|
2024
Q2 | – | Sell |
-71
| Closed | -$3.6K | – | 10095 |
|
|
2024
Q1 | $3.6K | Buy |
71
+51
| +255% | +$2.58K | ﹤0.01% | 7720 |
|
|
2023
Q4 | $1.17K | Buy |
+20
| New | +$947 | ﹤0.01% | 8385 |
|
|
2023
Q3 | – | Sell |
-62
| Closed | -$1.02K | – | 9972 |
|
|
2023
Q2 | $1.02K | Buy |
+62
| New | +$1.56K | ﹤0.01% | 8035 |
|
|
2022
Q4 | – | Sell |
-221
| Closed | -$5K | – | 11152 |
|
|
2022
Q3 | $5K | Sell |
221
-163
| -42% | -$4.83K | ﹤0.01% | 9229 |
|
|
2022
Q2 | $11K | Buy |
+384
| New | +$14.9K | ﹤0.01% | 7849 |
|
|
2021
Q4 | – | Sell |
-76
| Closed | -$14K | – | 10718 |
|
|
2021
Q3 | $14K | Buy |
76
+65
| +591% | +$12.6K | ﹤0.01% | 7597 |
|
|
2021
Q2 | $2K | Buy |
+11
| New | +$2.47K | ﹤0.01% | 8982 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 8413 |
|
|
2020
Q2 | – | Sell |
-37
| Closed | -$14.8K | – | 8358 |
|
|
2020
Q1 | $38K | Sell |
37
-23
| -38% | -$33.5K | ﹤0.01% | 6047 |
|
|
2019
Q4 | $78K | Buy |
60
+13
| +28% | +$18.3K | ﹤0.01% | 6119 |
|
|
2019
Q3 | $65K | Buy |
47
+36
| +327% | +$58.1K | ﹤0.01% | 6042 |
|
|
2019
Q2 | $25K | Buy |
+11
| New | +$32.4K | ﹤0.01% | 6469 |
|
|
2019
Q1 | – | Sell |
-7
| Closed | -$11K | – | 8168 |
|
|
2018
Q4 | $11K | Buy |
+7
| New | +$14.4K | ﹤0.01% | 7196 |
|
|
2018
Q3 | – | Hold |
0
| – | -$1K | – | 8268 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 7840 |
|
|
2018
Q1 | – | Sell |
-3
| Closed | -$8.99K | – | 7665 |
|
|
2017
Q4 | $14K | Hold |
3
| – | – | ﹤0.01% | 6816 |
|
|
2017
Q3 | $12K | Buy |
3
+2
| +200% | +$8.55K | ﹤0.01% | 6794 |
|
|
2017
Q2 | $4K | Sell |
1
-5
| -83% | -$21.2K | ﹤0.01% | 7219 |
|
|
2017
Q1 | $32K | Buy |
6
+3
| +100% | +$14K | ﹤0.01% | 5818 |
|
|
2016
Q4 | $14K | Hold |
3
| – | – | ﹤0.01% | 6734 |
|
|
2016
Q3 | $71K | Buy |
3
+1
| +50% | +$18.1K | ﹤0.01% | 5231 |
|
|
2016
Q2 | $30K | Sell |
2
-2
| -50% | -$45.7K | ﹤0.01% | 5937 |
|
|
2016
Q1 | $101K | Hold |
4
| – | – | ﹤0.01% | 4977 |
|
|
2015
Q4 | $119K | Sell |
4
-3
| -43% | -$98.9K | ﹤0.01% | 5078 |
|
|
2015
Q3 | $178K | Buy |
7
+2
| +40% | +$135K | ﹤0.01% | 4730 |
|
|
2015
Q2 | $388K | Buy |
5
+2
| +67% | +$183K | ﹤0.01% | 4324 |
|
|
2015
Q1 | $304K | Buy |
3
+2
| +200% | +$266K | ﹤0.01% | 4543 |
|
|
2014
Q4 | $86K | Buy |
+1
| New | +$73.2K | ﹤0.01% | 5864 |
|
Other funds holding TPST
VVM
VCM
VFT
SM
TRCT
UBS Group's TPST Position: Q1 2026 in Review
UBS Group reduced its Tempest Therapeutics (TPST) stake by 74% in Q1 2026, selling an estimated $31.4K and leaving 4,533 shares worth $7.43K. The position accounts for ﹤0.01% of the portfolio, ranked #8581.
UBS Group first reported a position in TPST in Q4 2014 and has held it in 32 quarters since. The position peaked at $388K in Q2 2015. 22 funds tracked by Wall St. Rank hold TPST as of Q1 2026.
- UBS Group held 4,533 shares of Tempest Therapeutics worth $7.43K as of Q1 2026.
- UBS Group sold 13,009 Tempest Therapeutics shares in Q1 2026, an estimated $31.4K.
- Tempest Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8581 holding.
- UBS Group first reported a position in Tempest Therapeutics in Q4 2014 and has held it in 32 quarters since.
- UBS Group's Tempest Therapeutics position peaked at $388K in Q2 2015.
- 22 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.